+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Zydus Cadila - logo

Zydus Cadila Pharmaceutical is a global healthcare provider. The origins of this group go back to 1952, however in 1995 this group restructured its operations and the Cadila group were taken over by the Zydus group. It is the only Indian pharma company to launch its own patented NCE. They developed a drug for diabetic dyslipidemia, Lipaglyn. This is the first drug to be approved for this disease. They are the 4th largest in the Indian pharma market. Other than their successful sales from India, Zydus gains a wider market share through its subsidiaries in the U.S, Europe (France and Spain), South Africa and Latin America. From their beginning in 1995 to today Zydus has shown major growth rates in revenue.

From
Onychomycosis Global Market Report 2024 - Product Thumbnail Image

Onychomycosis Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
Antifungals Global Market Report 2024 - Product Thumbnail Image

Antifungals Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
NLRP3 Protein Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

NLRP3 Protein Inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 80 Pages
  • Global
From
Epoetin alfa- Biosimilar Insight, 2022 - Product Thumbnail Image

Epoetin alfa- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Rituximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Rituximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
  • Global
From
Male Hypogonadism Global Market Report 2024 - Product Thumbnail Image

Male Hypogonadism Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Coronavirus (COVID-19) Current Therapy Global Market Report 2023 - Product Thumbnail Image

Coronavirus (COVID-19) Current Therapy Global Market Report 2023

  • Report
  • February 2023
  • 250 Pages
  • Global
From
Filgrastim - Biosimilar Insight, 2022 - Product Thumbnail Image

Filgrastim - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Pegfilgrastim- Biosimilar Insight, 2022 - Product Thumbnail Image

Pegfilgrastim- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Chemotherapy Induced Anemia - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy Induced Anemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Vaccine Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Vaccine Collaboration and Licensing Deals 2016-2024

  • Report
  • November 2024
  • 400 Pages
  • Global
From
Loading Indicator